Inhibikase Therapeutics Reports Results from Phase 2 201 Trial for Risvodetinib
On January 29, 2025, Inhibikase Therapeutics, Inc. (NYSE:IKT) disclosed findings from the Phase 2 201 trial (the “201 Trial”) evaluating risvodetinib, a selective inhibitor of non-receptor Abelson Tyrosine Kinases, in untreated Parkinson’s disease. The 201 Trial involved 126 individuals with untreated Parkinson’s disease who were, on average, 14 months post-diagnosis. Participants received doses of 50 […]
More Stories
Dolly Parton, queen of country music, dies at 80
By Reuters Aug 25 (Reuters) – Dolly Parton was around six when she wrote her first song: “Little Tiny Tasseltop,”...
Canada’s Dollar-for-Dollar Tariff Response Exposes a Trade Relationship America Should Have Reexamined Decades Ago
By Stephen Zogopoulos, USNN World News Canada has now formally answered Washington’s latest tariffs with what it calls a “dollar-for-dollar,...
South Carolinians Go to Polls for Key Republican Senate Primary
By Joseph Lord CHARLESTON, S.C.—South Carolina voters will head to the polls today to make their pick in a runoff...
Iran Vows to Retaliate After US Rolls Out ‘Economic D-Day’ Sanctions
By Owen Evans Iran has promised to retaliate against the United States after Washington rolled out an “economic D-Day” sanctions...
ICE Arrests More Than 1,300 Illegal Immigrants in Virginia, Maryland in 2-Week Operation
By Aldra Fredly Immigration and Customs Enforcement (ICE) arrested more than 1,300 illegal immigrants during a two-week operation in Virginia...
Bessent Warns China, Others Not to Test US Resolve on Iran Sanctions
By Andrew Moran and Emel Akan Bessent, at an Aug. 24 news conference, unveiled the contours of the administration’s sweeping...